Efficacy and safety of certolizumab pegol after incomplete response to DMARDS in RA patients with low moderate disease activity: results from CERTAIN, a phase IIIB study

Authors
Category Primary study
JournalAnn Rheum Dis
Year 2011
This article has no abstract
Epistemonikos ID: 1916dd89a8608cadb0153fdf71a140246c915b1d
First added on: Jun 26, 2016